Restructuring dynamics of DU 145 and LNCaP prostate cancer spheroids.
Neoplastic cells acquire multidrug resistance as they assemble into multicellular spheroids. Image analysis and Monte Carlo simulation provided an insight into the adhesion and motility events during spheroid restructuring in liquid-overlay culture of DU 145 and LNCaP human prostate cancer cells. Irregularly shaped, two-dimensional aggregates restructured through incremental cell movements into three-dimensional spheroids. Of the two cultures examined, restructuring was more pronounced for DU 145 aggregates. Motile DU 145 cells formed spheroids with a minimum cell overlay of 30% for 25-mers as estimated by simulation versus 5% for adhesive LNCaP cells in aggregates of the same size. Over 72 h, the texture ratio increased from 0.55 +/- 0.05 for DU 145 aggregates with projected areas exceeding 2000 microm2 to a value approaching 0.75 +/- 0.02 (P < 0.05). For LNCaP aggregates of comparable size, the increase in texture ratio was more modest, less than 15% during the same time period (P < 0.05). Combined, these data suggest that motility events govern the overall rate of spheroid restructuring. This information has application to the chemosensitization of solid tumors and kinetic modeling of spheroid production.
Song
Hong
H
Department of Chemical and Biomolecular Engineering, Lindy Boggs Center, Tulane University, New Orleans, Louisiana 70118, USA.
Jain
Shamik K
SK
Enmon
Richard M
RM
O'Connor
Kim C
KC
D002449:Cell Aggregation; D018929:Cell Culture Techniques; D002465:Cell Movement; D006801:Humans; D008297:Male; D009010:Monte Carlo Method; D011471:Prostatic Neoplasms; D018874:Spheroids, Cellular / Q000166:cytology* / Q000378:metabolism*; D014407:Tumor Cells, Cultured
Biotechnol Bioeng. 2002 Dec 5;80(5):580-8
12355469
Proteins. 2000 Mar 1;38(4):414-27
10707028
Eur J Cancer. 2003 Jan;39(2):136-46
12509944
Tissue Eng. 2002 Dec;8(6):1071-81
12542952
Med Phys. 2003 Feb;30(2):144-57
12607832
Cancer. 1996 May 1;77(9):1862-72
8646686
Cancer Res. 2002 Mar 1;62(5):1266-70
11888888
Int J Cancer. 1987 Oct 15;40(4):557-63
3478309
J Cancer Res Clin Oncol. 1995;121(4):193-202
7751317
CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26
12568441
Pharm Res. 1999 Apr;16(4):486-93
10227701
J Theor Biol. 1978 Mar 7;71(1):103-40
642518
Biotechnol Prog. 2003 Nov-Dec;19(6):1742-9
14656150
Curr Oncol Rep. 2003 May;5(3):250-7
12667424
Proc Natl Acad Sci U S A. 1999 Jan 19;96(2):471-6
9892657
J Urol. 2001 Jan;165(1):130-5
11125381
Int J Cancer. 1998 Mar 16;75(6):855-63
9506530
Biophys J. 1992 Jan;61(1):119-28
1540685
Anticancer Res. 1998 Nov-Dec;18(6A):4147-58
9891460
Biotechnol Bioeng. 2001 Mar 20;72(6):579-91
11460249
Cancer Lett. 1991 Nov;60(2):113-9
1933835
Cancer Commun. 1991 Aug;3(8):255-64
1653586
Cancer Res. 1977 Oct;37(10):3639-43
908012
In Vitro Cell Dev Biol Anim. 1997 May;33(5):344-51
9196892
J Natl Cancer Inst. 1996 Sep 18;88(18):1285-96
8797768